Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach.
第一作者:
Tao,Meng
第一单位:
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China.
作者:
医学主题词
投药, 口服(Administration, Oral);动物(Animals);二苯甲基化合物(Benzhydryl Compounds);CHO细胞(CHO Cells);细胞, 培养的(Cells, Cultured);仓鼠亚科(Cricetinae);仓鼠属(Cricetulus);半数抑制浓度(Inhibitory Concentration 50);男(雄)性(Male);分子结构(Molecular Structure);哌嗪类(Piperazines);大鼠(Rats);大鼠, Sprague-Dawley(Rats, Sprague-Dawley);受体, 大麻酚, CB1(Receptor, Cannabinoid, CB1);重组蛋白质类(Recombinant Proteins);构效关系(Structure-Activity Relationship)
DOI
10.1016/j.ejmech.2009.12.018
PMID
20047779
发布时间
2010-02-17
- 浏览7
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



